×
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
OTCMKTS:CNBX

CNBX Pharmaceuticals Stock Forecast, Price & News

$3.54
-0.21 (-5.60%)
(As of 06/30/2022 11:21 AM ET)
Add
Compare
Today's Range
$3.54
$3.54
50-Day Range
$3.50
$10.40
52-Week Range
$3.00
$23.18
Volume
947 shs
Average Volume
959 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNBX Stock Forecast (MarketRank)

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
CNBX Pharmaceuticals logo

About CNBX Pharmaceuticals (OTCMKTS:CNBX)

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.

CNBX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Cannabis
Sector
Medical
Current Symbol
OTCMKTS:CNBX
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A














CNBX Pharmaceuticals Frequently Asked Questions

How has CNBX Pharmaceuticals' stock price performed in 2022?

CNBX Pharmaceuticals' stock was trading at $10.68 at the start of the year. Since then, CNBX stock has decreased by 66.9% and is now trading at $3.54.
View the best growth stocks for 2022 here
.

When did CNBX Pharmaceuticals' stock split? How did CNBX Pharmaceuticals' stock split work?

Shares of CNBX Pharmaceuticals reverse split on the morning of Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of CNBX Pharmaceuticals stock prior to the reverse split would have 1 shares after the split.

Who are CNBX Pharmaceuticals' key executives?

CNBX Pharmaceuticals' management team includes the following people:
  • Mr. Gabriel Yariv, Pres, COO & Exec. Chairman (Age 45, Pay $241.79k)
  • Mr. Eyal Barad, Co-Founder, CEO & Director (Age 57, Pay $268.72k)
  • Dr. Eyal Ballan Ph.D., Co-Founder & CTO (Age 49, Pay $225.63k)
  • Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52, Pay $76.4k)
  • Noam Permont, VP of PR & Investor Relations
  • Dr. Sigalit Ariely-Portnoy Ph.D., Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board (Age 58)
  • Dr. Tal Mofkadi Ph.D., Financial Advisor & Member of Advisory Board
  • Mr. Yasha Borstein, Chief Data Officer (Age 59)
  • Dr. Yaakov Waksman, Head of Cannabidiol Research (Age 70)
  • Dr. Ilya Reznik M.D., Head of Neuropsychiatry Devel.

What other stocks do shareholders of CNBX Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), OrganiGram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).

What is CNBX Pharmaceuticals' stock symbol?

CNBX Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX."

How do I buy shares of CNBX Pharmaceuticals?

Shares of CNBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CNBX Pharmaceuticals' stock price today?

One share of CNBX stock can currently be purchased for approximately $3.54.

How many employees does CNBX Pharmaceuticals have?

CNBX Pharmaceuticals employs 10 workers across the globe.

How can I contact CNBX Pharmaceuticals?

CNBX Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The official website for CNBX Pharmaceuticals is www.cannabics.com. The company can be reached via phone at (877) 424-2429.

This page (OTCMKTS:CNBX) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.